WO2020004580A1 - Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique - Google Patents

Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique Download PDF

Info

Publication number
WO2020004580A1
WO2020004580A1 PCT/JP2019/025696 JP2019025696W WO2020004580A1 WO 2020004580 A1 WO2020004580 A1 WO 2020004580A1 JP 2019025696 W JP2019025696 W JP 2019025696W WO 2020004580 A1 WO2020004580 A1 WO 2020004580A1
Authority
WO
WIPO (PCT)
Prior art keywords
body odor
phase
odor
cells
skin
Prior art date
Application number
PCT/JP2019/025696
Other languages
English (en)
Japanese (ja)
Inventor
一彦 安藤
和江 ▲高▼山
審爾 吉柳
健太郎 広瀬
祐子 牧岡
Original Assignee
一丸ファルコス株式会社
コンビ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 一丸ファルコス株式会社, コンビ株式会社 filed Critical 一丸ファルコス株式会社
Priority to JP2020527655A priority Critical patent/JPWO2020004580A1/ja
Publication of WO2020004580A1 publication Critical patent/WO2020004580A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the present invention relates to a body odor generation inhibitor containing a lactic acid bacterium, and more specifically, a body odor generation inhibitor having a form such as a skin external preparation, a laundry composition or a sanitary sheet material containing Enterococcus faecalis EC-12, which is a lactic acid bacterium. Agent.
  • the odor be odorless, and the odor is strongly disliked.
  • the so-called aging odor seen after middle-aged and older people can be said to be one of the odors particularly disliked.
  • This body odor that specifically occurs with aging has been found to be due to 2-nonenal, a type of unsaturated aldehyde.
  • 2-Nonenal has a tendency to specifically increase after the age of 40, which is considered to be the age at which aging odors occur (Non-Patent Document 1), and its generation mechanism is described in terms of unsaturated fatty acids ( (9-hexadecenoic acid) is supposed to be caused by oxidation or decomposition by indigenous skin bacteria.
  • unsaturated fatty acids (9-hexadecenoic acid)
  • Non-Patent Document 2 Non-Patent Document 2
  • the lactic acid bacterium Enterococcus faecalis EC-12 promotes the production of glycerol derived from Staphylococcus epidermidis and the production of antibacterial peptide derived from skin epidermal keratinocytes, thereby maintaining a healthy skin surface condition.
  • Patent Document 3 it has been reported (Patent Document 3), its effect on indigenous skin bacteria causing body odor is not clear.
  • an object of the present invention is to reduce unpleasant body odor by specifically reducing the ratio of harmful bacteria that are resident on the skin and cause body odor.
  • the present inventors have investigated various lactic acid bacteria in order to solve the above problems, and as a result of intensive studies, have found that the cells of lactic acid bacterium Enterococcus faecalis EC-12, especially the heat-killed cells of the lactic acid bacterium, are usually in the skin. I found that the flora was prepared.
  • This lactic acid bacterium is the proportion of Corynebacterium, which is a bacterium that produces aromatic amino acids, steroids, and thiol compounds, among the resident bacteria that cause unpleasant body odor, and thiol in the thiol compound.
  • a body odor generation inhibitor comprising, as an active ingredient, cells of Enterococcus faecalis EC-12 strain (accession number: FERM BP-10284).
  • the aqueous composition has an effective amount for dispersing the cells.
  • the body odor generation inhibitor according to [1] comprising a water-soluble polymer compound.
  • the body odor generation inhibitor according to [2], wherein the composition has a viscosity at 25 ° C of 1,000 mPa ⁇ s or more.
  • [4] The method according to any one of [1] to [3], for inhibiting the growth of one or more resident skin bacteria belonging to the genus Staphylococcus, Corynebacterium or Micrococcus.
  • Body odor generation inhibitor [5] The method according to any one of [1] to [4], for suppressing generation of a body odor comprising any of an amine odor, a thiol odor, a fatty acid odor, and a 2-nonenal odor, or a mixed odor thereof.
  • Body odor generation inhibitor [6] The body odor generation inhibitor according to any one of [1] to [5], which is in the form of a skin external preparation.
  • Application of a composition containing cells of Enterococcus faecalis EC-12 strain (Accession No. FERM BP-10284) to a subject in need of suppressing body odor generation Suppression method.
  • the body odor generation inhibitor of the present invention contains bacteria of Enterococcus faecalis EC-12 strain (Accession No. FERM @ BP-10284) as an active ingredient, thereby suppressing the presence of indigenous bacteria causing odor. Proliferation can be specifically suppressed, and generation of body odor can be effectively suppressed.
  • FIG. 2 shows the results of quantifying amines among odor components collected from the soles of a foot in a human monitor test using a foot spray containing heat-killed Enterococcus faecalis EC-12 cells. It is explanatory drawing of the test design of the sebum score quantitative test by the sebum collection method. 4 shows the results of a sebum score quantitative test on the forehead.
  • body odor generation inhibitor refers to a composition containing, as an active ingredient, cells of Enterococcus faecalis EC-12 strain (Accession No. FERM @ BP-10284), It means a composition that is effective for preventing or improving the occurrence of body odor by acting on bacteria.
  • the body odor generation inhibitor of the present invention as described in detail below, lotions as cosmetics and quasi-drugs, emulsions, creams, medicated cosmetics such as packs, soaps, and lotions, emulsions, creams as pharmaceuticals, Includes skin external preparations such as ointments, and health care products such as laundry compositions and sanitary sheets.
  • compositions as an intermediate product for producing these products may be a composition as an intermediate product for producing these products.
  • external preparations for skin are preferred, and in particular, aqueous compositions in which the active ingredient according to the present invention is suspended and adjusted to have a predetermined viscosity are preferred.
  • the “composition” may take various forms such as a liquid, a cream, a gel, or a powder.
  • the composition usually contains water in an amount of 1% by weight or more, preferably 5% by weight or more, more preferably 20% by weight or more, and still more preferably 50% by weight or more. means.
  • the water contained in the aqueous composition of the present invention may be pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.
  • distilled water ordinary water, purified water, sterilized purified water, water for injection, distilled water for injection, and the like can be used. These definitions are based on the 15th revised Japanese Pharmacopoeia.
  • the indication of the content of each component in the composition indicates "% by weight" unless otherwise specified.
  • the aqueous composition of the present invention can take various formulation forms depending on the purpose.
  • examples of the form of the aqueous composition of the present invention include liquid preparations, semisolid preparations (such as ointments) and the like.
  • it is a liquid preparation.
  • the “viscosity” in the present specification refers to an aqueous composition obtained by dispersing the active ingredient of the present invention in water to a predetermined concentration by a B-type viscometer (spindle No. 3, rotation speed 10 rpm). It is a value measured at ° C.
  • lactococci are used as an active ingredient of the body odor generation inhibitor. More preferably, it is a bacterium belonging to the genus Enterococcus, and even more preferably, it is Enterococcus faecalis.
  • Enterococcus faecalis include, for example, Enterococcus faecalis EC-12 strain, ATCC19433, ATCC14508, ATCC23655, IFO16803, IFO16804, and the like, or mutants thereof.
  • the lactic acid bacterium used as an active ingredient the above-mentioned EC-12 strain is most preferable.
  • the “mutant strain” refers to a strain obtained by mutating a specific strain by a method well known to those skilled in the art to the extent that the person skilled in the art does not change its properties, or the person skilled in the art confirms that it is equivalent thereto It is meant to include what can be done.
  • the Enterococcus faecalis EC-12 strain (Enterococcus faecalis EC-12) was acquired on February 25, 2005 (the original deposit date) by the National Institute of Advanced Industrial Science and Technology (AIST) and the Patent Organism Depositary Center ( $ 305-8566, deposited at 1-1, Higashi 1-1, Tsukuba, Ibaraki, Japan, No. 6).
  • the accession number is FERM @ BP-10284.
  • live cells and / or dead cells can be used, but preferably dead cells are used from the viewpoint of the storage stability of the agent, and more preferably, the above-mentioned lactococci are known.
  • Heat sterilized cells obtained by sterilization by a heat treatment means are used. Heat-killed bacterial cells are collected from a culture obtained by culturing the lactic acid bacterium according to a conventional method, filtration, centrifugation, etc., recovering the bacterial cells, washing with water, suspending in water or the like, and heating. If necessary, it can be prepared by concentrating and drying. Alternatively, it may be prepared by firing and steaming the cells.
  • the sterilized bacterial cell powder obtained by heat-treating the EC-12 strain is commercially available under the trade name "EC-12” (manufactured by Combi Corporation) or "La Flora EC-12” (manufactured by Ichimaru Falcos Corporation). I have. Therefore, in the present invention, such a commercially available product may be used as lactic acid bacterium used as an active ingredient.
  • the number of lactococci can be measured by a microscopic counting method, a turbidity method, a call counter method, an enzyme-linked immunosorbent assay (ELISA or SYBR Green) according to a conventional method.
  • ELISA enzyme-linked immunosorbent assay
  • the number of lactic acid bacteria in the body odor generation inhibitor of the present invention can be adjusted to a desired numerical range by mixing an appropriate amount of the above-mentioned commercially available products and the like.
  • the body odor generation inhibitor according to the present embodiment is arbitrarily selected and used in combination with the components and additives exemplified below as necessary according to the respective formulations of the external preparation for the skin, the laundry composition, the sanitary sheet material, and the like. Can be manufactured.
  • the blending amount in these formulation systems is not particularly limited, but usually, it is considered to be preferably about 0.0001 to 50% by weight.
  • Alcohols Natural alcohols such as ethanol, isopropanol, lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, lanolin alcohol, cholesterol, phytosterol, and phenoxyethanol; and synthetic alcohols such as 2-hexyldecanol, isostearyl alcohol, and 2-octyldodecanol. .
  • Esters Isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, oleyl oleate, decyl oleate, octyl dodecyl myristate, hexyl decyl dimethyloctanoate, cetyl lactate, myristyl lactate, Diethyl phthalate, dibutyl phthalate, lanolin acetate, ethylene glycol monostearate, propylene glycol monostearate, propylene glycol dioleate and the like.
  • Metal soaps Aluminum stearate, magnesium stearate, zinc stearate, calcium stearate, zinc palmitate, magnesium myristate, zinc laurate, zinc undecylenate and the like.
  • gum sugar or water-soluble polymer compound gum arabic, benzoin gum, dammar gum, guaiac oil, Irish moss, karaya gum, tragacanth gum, carob gum, quinseed, agar, casein, lactose, fructose, sucrose or esters thereof, Trehalose or a derivative thereof, dextrin, gelatin, pectin, starch, carrageenan, carboxymethyl chitin or chitosan, hydroxyalkyl (C2-C4) chitin or chitosan to which alkylene (C2-C4) oxide such as ethylene oxide is added, low molecular weight chitin Or chitosan, chitosan salt, sulfated chitin or chitosan, phosphorylated chitin or chitosan, alginic acid or a salt thereof, hyaluronic acid or a salt thereof, chondroitin sulfate or
  • Surfactant Anionic surfactant (alkyl carboxylate, alkyl sulfonate, alkyl sulfate, alkyl phosphate), cationic surfactant (alkyl amine, alkyl quaternary ammonium salt), amphoteric Surfactant: Carboxylic acid type amphoteric surfactant (amino type, betaine type), sulfate ester type amphoteric surfactant, sulfonic acid type amphoteric surfactant, phosphate type amphoteric surfactant, nonionic surfactant ( Ether type nonionic surfactant, ether ester type nonionic surfactant, ester type nonionic surfactant, block polymer type nonionic surfactant, nitrogen-containing nonionic surfactant), other surfactants ( Natural surfactants, derivatives of protein hydrolysates, polymeric surfactants, surfactants containing titanium and silicon, Carbonized surfactants).
  • Vitamin A group retinol, retinal (vitamin A1), dehydroretinal (vitamin A2), carotene, lycopene (provitamin A), vitamin B group: thiamine hydrochloride, thiamine sulfate (vitamin B1), Riboflavin (vitamin B2), pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), folic acids, nicotinic acids, pantothenic acids, biotins, choline, inositols, vitamin C group: vitamin C acid or its derivative, vitamin D group: Ergocalciferol (vitamin D2), cholecalciferol (vitamin D3), dihydrotaxerol, vitamin E group: vitamin E or its derivatives, ubiquinones, vitamin K group: phytonadione (vitamin K1), menaquinone (vitamin K2) , Menadione (vitamin K3), menadiol
  • valine Various amino acids valine, leucine, isoleucine, threonine, methionine, phenylalanine, tryptophan, lysine, glycine, alanine, asparagine, glutamine, serine, cysteine, cystine, tyrosine, proline, hydroxyproline, aspartic acid, glutamic acid, hydroxylysine , Arginine, ornithine, histidine and the like, and their sulfates, phosphates, nitrates, citrates, and amino acid derivatives such as pyrrolidone carboxylic acid.
  • an additive derived from a plant or animal-based material is applied to a systemic or topical external preparation or cosmetics, the skin and hair are protected, the moisturizer is improved, the feel / feel is improved, the flexibility is imparted, and stimulation is provided.
  • Mitigation, alleviation of stress by aroma, cell activation (prevention of cell aging), suppression of inflammation, improvement of skin and hair quality, prevention and improvement of rough skin, hair growth, hair growth, hair loss prevention, gloss imparting, cleaning effect In addition to cosmetic effects such as alleviation of fatigue, promotion of blood flow, and warm bath effect, effects such as fragrance, deodorization, thickening, preservation, and buffering can be expected.
  • the method for culturing Enterococcus lactic acid bacterium as an active ingredient is not particularly limited, including a conventionally known lactic acid bacterium culturing method. It can be manufactured by the method described above. From a culture obtained by culturing Enterococcus lactic acid bacterium according to a conventional method, for example, the cells are collected by a method such as filtration, centrifugation, etc., washed with water, suspended in water, etc., and heat-treated. It can be prepared by concentrating and drying according to. It may be carried out using a commonly used spray drying, freeze dryer or the like. In some cases, before or after sterilization treatment by heating or before or after drying treatment, enzyme treatment, surfactant treatment, grinding and pulverization treatment can also be performed, and those obtained by these treatments can also be used in the present invention. Of the killed cells or processed products thereof.
  • the water used for washing and suspension includes pure water, tap water, well water, mineral water, mineral water, hot spring water, spring water, fresh water, and the like, as well as those subjected to various treatments.
  • Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, and buffering. Therefore, water that can be used as an extraction solvent in the present invention includes purified water, heat-treated water, ion-exchanged water, physiological saline, various buffers, and the like.
  • the Lactococcus genus Enterococcus obtained as described above may be in any state of a composition such as a dry powder or an aqueous composition, but when used as an intermediate material, the Lactococcus genus Enterococcus is 5 ⁇ per gram. It is preferable that the amount is adjusted to be 10 11 or more, particularly preferably 5 ⁇ 10 12 or more, when it is incorporated into various forms of drugs, quasi-drugs, and cosmetics. In the case of a skin external preparation, a laundry composition, and a sanitary sheet material as final products, for example, about 1 ⁇ 10 11 to 5 ⁇ 10 12 of the above-mentioned Lactococcus genus Enterococcus per one use. The formulation has been adjusted to apply.
  • the body odor generation inhibitor according to the present embodiment is not limited to a composition such as a powder composition, a gel composition (including a hard gel composition), and an aqueous composition.
  • an aqueous composition may be preferable from the viewpoint of production of the composition.
  • a composition containing a bacterial cell of Enterococcus faecalis EC-12, which is an active ingredient, in an aqueous medium at a concentration of at least 5 ⁇ 10 8 cells / g is preferable. More preferably, it is an aqueous composition contained at a concentration of 1 ⁇ 10 9 / g or more, more preferably 5 ⁇ 10 9 / g or more by suspension or the like.
  • the aqueous composition it is preferable to contain a viscosity modifier such as a water-soluble polymer compound so that the active ingredient is in a uniform dispersion state.
  • a viscosity modifier such as a water-soluble polymer compound
  • the lower limit of the value measured using a B-type viscometer at 25 ° C. is 100 mPa ⁇ s or more, preferably 500 mPa ⁇ s or more, and particularly preferably. Is not less than 1000 mPa ⁇ s, and the upper limit of the value measured using a B-type viscometer at 25 ° C.
  • the concentration of the water-soluble polymer compound added to the aqueous composition to achieve such a viscosity can be appropriately set by those skilled in the art. For example, about 0.1 to 0.2% by weight of a water-soluble polymer compound such as a carboxyvinyl polymer or xanthan gum is added.
  • the active ingredient contained in the body odor generation inhibitor of this embodiment on suppressing human body odor is not always clear, and is not limited by any theory, but the following mechanism of action It is estimated to be based on That is, it is considered that the active ingredient of the present invention maintains the diversity of resident bacteria by some mechanism by interacting with cells constituting the epidermis of the skin and resident bacteria existing in the skin. In other words, the skin-resident bacteria that generate odorous substances that cause unpleasant body odors are prevented from growing specifically, while the growth of useful bacteria such as Staphylococcus epidermidis is promoted to balance the skin-resident bacteria. it is conceivable that.
  • Examples of indigenous skin bacteria that generate odorous substances include, for example, Staphylococcus forminis, which is a bacterium producing thiol compounds, particularly thiol alcohol, and Corynebacterium, which is a producer of aromatic amino acids, steroids, and thiol compounds.
  • Staphylococcus forminis which is a bacterium producing thiol compounds, particularly thiol alcohol
  • Corynebacterium which is a producer of aromatic amino acids, steroids, and thiol compounds.
  • bacteria of the genus and Staphylococcus aureus, which is pathogenic and emits a fatty acid smell. It is shown in Tables 2 to 5, which are experimental results of examples, that the body odor generation inhibitor of the present embodiment suppresses the growth of these bacteria resident on the skin.
  • it is a body odor generation inhibitor for suppressing the growth of one or more resident bacteria belonging to the genus Staphylococcus, Corynebacterium or Micrococcus. More preferably, the growth of bacteria of the genus Staphylococcus, particularly Staphylococcus horminis and Staphylococcus aureus, can be suppressed.
  • the body odor source substances such as amines / thiol compounds / 2-nonenal / heptanal, octanal, methylheptene, nonanal, etc., are further reduced to secretions from the body. It is thought to suppress the generation of other body odor sources contained (see Table 7). Therefore, in a preferred embodiment of the present invention, there is provided a body odor generation inhibitor for suppressing the generation of a body odor composed of any of an amine odor, a thiol odor, a fatty acid odor, and a 2-nonenal odor, or a mixed odor thereof. .
  • the body odor generation inhibitor of the present embodiment may be used in the form of ampules, capsules, powders, granules, liquids, gels, air bubbles, emulsions, sheets, mist, liquid sprays, powder sprays, etc.
  • Topical or topical skin external preparations for example, basic makeup such as lotion, emulsion, cream, ointment, lotion, oil, pack, etc.
  • Cleanser skin cleanser, massage soap, cleansing agent, hair remover, depilatory, shaving treatment agent, after-shave lotion, pre-show lotion, shaving cream, foundation Makeup, lipstick, blusher, eyeshadow, eyeliner, mascara, etc., perfumes, plasters, tapes Preparations, patches, aerosols, etc.)
  • medicinal or / and cosmetic preparations applicable to the scalp / hair eg, shampoos, rinses, hair treatments, pre-hair treatments, permanent liquids, hair dyes
  • Hair styling agents hair tonics, hair restoration / hair restoration, aerosols, etc.
  • a sanitary sheet material to which a body odor generation inhibitor containing Enterococcus faecalis EC-12 strain (accession number FERM BP-10284) according to the present invention as an active ingredient is adhered (particularly, a nonwoven fabric sanitary sheet material) 8) sanitary ware, cosmetic cotton, cosmetic facial sheet, body wet sheet, antiperspirant nonwoven fabric, armpit sweat pad, napkin, tampon, etc., sanitary ware, vaginal sheet, sheet hygiene Cotton, wet tissue, baby disposable diapers, adult disposable diapers, pillow cover sheets, bedding pat sheets, shoe insole sheets and the like can be mentioned.
  • ⁇ it is particularly preferable to be in the form of an external preparation for skin.
  • other cosmetic effects can be achieved at the same time. For example, an effect as a sebum suppressant that reduces skin shine and greasy by suppressing the generation of sebum that causes body odor is expected.
  • laundry compositions In another preferred embodiment, mention may be made of laundry compositions.
  • the laundry composition of this embodiment comprises, in addition to the active ingredient of the present invention, a surfactant, detergent builder or complexing agent such as zeolites, diphosphates, triphosphates, phosphonates, carbonates, citrates, nitrilotri.
  • a surfactant such as zeolites, diphosphates, triphosphates, phosphonates, carbonates, citrates, nitrilotri.
  • Acetic acid, ethylenediaminetetraacetic acid, diethylenetriaminehexaacetic acid, alkyl- or alkynylsuccinic acid, soluble silicates or layered silicates can be included.
  • Preferred anionic surfactants for use in the laundry composition include sulfates of higher alcohols, sulfates of ethoxylated higher alcohols, alkylbenzene sulfonates, paraffin sulfonates, ⁇ -olefin sulfonates, ⁇ -Sulfo fatty acid salts or ester salts thereof, and fatty acid salts.
  • a linear alkylbenzene sulfonic acid salt having an alkyl chain having 10 to 18 (preferably 12 to 14) carbon atoms and an ⁇ -sulfofatty acid alkyl ester salt having 10 to 20 carbon atoms are preferable.
  • the counter ion include an alkali metal, an alkaline earth metal, ammonia, and an alkanolamine.
  • nonionic surfactant examples include an ethylene oxide (hereinafter, referred to as “EO”) adduct of a higher alcohol, an EO / propylene oxide (hereinafter, referred to as “PO”) adduct, a fatty acid alkanolamide, an alkyl (poly) glycoside, and the like.
  • EO ethylene oxide
  • PO propylene oxide
  • adduct of 1 to 10 moles of EO of an alcohol having 10 to 16 carbon atoms is preferable in terms of removing sebum stains, hard water resistance, and biodegradability.
  • an amine salt or a quaternary ammonium salt can be used.
  • a quaternary ammonium salt of a di-long-chain alkyl type is preferable, and a quaternary ammonium salt having a linking group such as -COO-, -OCO-, -NHCO-, -CONH- in the alkyl group may be used.
  • the amphoteric surfactant include a carbobetaine type and a sulfobetaine type amphoteric surfactant.
  • components that can impart properties characteristic of a laundry composition such as detergents and finishing agents (softeners, sizing agents, etc.), can be contained.
  • a washing composition such as a detergent and a finishing agent (softener, sizing agent, etc.)
  • a washing composition having an effect of suppressing body odor can be obtained. Can be.
  • the laundry composition of the present embodiment is preferably intended for textiles such as clothing and bedding. Further, the laundry composition of the present invention can be applied as a laundry composition such as a detergent composition, a softener composition, and a sizing composition.
  • a further embodiment includes a sanitary sheet material.
  • the sanitary sheet in this embodiment is obtained by attaching the active ingredient of the present invention to a fiber base material.
  • the method for attaching the active ingredient of the present invention to the fiber base material is not particularly limited, and examples thereof include a printing method, a pad method, a coating method, and a jet printing method.
  • a printing method a printing paste and a liquid composition containing the active ingredient of the present invention are adhered to a fiber base material using a screen printing method. After that, it is dried by heating and fixed on the fiber base material, which is preferable in that the active ingredient can be stably fixed on the surface of the fiber base material and the production yield is good.
  • the amount of the active ingredient of the present invention in the fiber product can be appropriately set according to the type and use of the fiber base material, and is usually 0.001 to 30% by weight, preferably 0 to 30% by weight, based on the weight of the fiber product. 0.01 to 10% by weight. Within such a range, the active ingredient of the present invention can be stably fixed to the fiber base material.
  • the bacterium used as an active ingredient is a bacterium belonging to the genus Enterococcus. More preferably, the bacterium is Enterococcus faecalis.
  • Enterococcus faecalis examples include strains such as Enterococcus faecalis EC-12 (accession number FERM BP-10284), ATCC 19433, ATCC 14508, ATCC 23655, IFO 16803, IFO 16804, and mutants thereof.
  • EC-12 is most preferable.
  • mutant strain refers to a strain that has been mutated by a method known to those skilled in the art to a specific strain within a range that does not affect the properties of the strain, or is equivalent to the same. It is meant to include those that can be confirmed.
  • Enterococcus faecalis EC-12 (accession number: FERM BP-10284) manufactured by Combi Corporation was used.
  • the composition of the spray (uniformly mixed) for application to human feet and torso is as follows. 1. Placebo group (spray B) ⁇ Methylparaben (Platings-M, Ueno Pharmaceutical Co., Ltd.) 0.20% ⁇ 1,3-butanediol (Daicel Corporation) 5.00% ⁇ Water 94.8% 2.
  • EC-12 administration group (Spray A) -Enterococcus lactic acid bacterium heat-treated dead cells 0.10 w / v% ⁇ Methylparaben (Platings-M, Ueno Pharmaceutical Co., Ltd.) 0.20% ⁇ 1,3-butanediol (Daicel Corporation) 5.00% ⁇ Water 94.7%
  • Table 1 shows Simpson's Index and Shannon Entropy, which are indicators of the diversity of bacterial species obtained by the 16s rRNA analysis. The higher the diversity of the bacterial species, the closer the value of Simpson's Index to 1 and the lower the value of Shannon Entropy. From these analysis results, it is clear that the diversity of bacterial species is increased when Spray A containing heat-killed cells of Enterococcus lactic acid bacterium is used as compared to when Placebo Spray B containing no test substance is used. It became.
  • Table 2 shows the results of the ratio of Staphylococcus hominis
  • Table 3 shows the results of the ratio of Cornebacterium
  • Table 4 shows the results of the ratio of Micrococcus
  • Table 5 shows the results of the ratio of Staphylococcus aureus.
  • the percentage of Staphylococcus hominis was reduced by spray A spraying.
  • 29 bacterial species were detected, and the ratio of all bacterial species was reduced by spray A.
  • Three types of skin-resident bacteria belonging to the genus Micrococcus were detected, and the proportion of all the bacteria decreased by spray A spraying.
  • the proportion of Staphylococcus aureus also decreased.
  • the “mixed gel” in the present example is a gel containing heat-killed cells of Enterococcus lactic acid bacterium (Enterococcus faecalis), and the compounding ratio of the killed cells is 0.1% (see Table 1). 9).
  • Table 9 shows the formulation (composition) of the compounding gel.
  • a predetermined skin surface of the subject's forehead is blotted using a blotting film (26 mm ⁇ 24 mm) to collect sebum, and the blotting film is scanned using imageRUNNER @ ADVANCE @ c5540F (Canon Inc.). And ImageJ (National Institutes of Health, USA).
  • the score of a film coated with triglyceride was set as 100 as a positive control, the score of a film coated with nothing was set as 0 as a negative control, and the sebum score was scored from 0 to 100. Quantified.
  • FIG. 3 shows that the top 25% of subjects who had a high sebum score based on the sebum score of the first week, which is the acclimation period (four A group, three B group), had their sebum scores at the third and fifth weeks. It is the result of measuring the sebum score of the forehead measured on the weekend and plotting the relative value with the sebum score of the first week. It was found that the sebum score of the subjects to which the combination gel was applied was decreased in both the group A and the group B, and that the decrease was significantly reduced especially in the group A. From these results, it was shown that an external preparation for skin containing heat-killed cells of Enterococcus lactic acid bacterium (Enterococcus faecalis) has a sebum-suppressing action.
  • Enterococcus lactic acid bacterium Enterococcus faecalis
  • phase A Ethanol 10.00% Carbomer Na 0.50% (B phase) Water 28.60% (Bis-stearyl PEG / PPG-8 / 6 SMDI / PEG-400) copolymer, water (1% aqueous solution) 50.00% (C phase) Ethanol 5.00% Menthol 0.50% Benzalkonium chloride (50% aqueous solution) 0.05% (D phase) 5.00% of water 0.35% of zinc phenolsulfonate Enterococcus lactic acid bacterium heat-treated dead cells 0.01-1% (appropriate amount)
  • Body Lotion (W / O Emulsion) Alkyl benzoate (C12-15) 1.00% Beeswax 3.00% (Caprylic acid / capric acid) Palm alkyl 6.80% 6.80% dicaprylyl ether Dimethicone, dimethiconol 6.60% Mg stearate 2.00% 6.80% polyglyceryl dipolyhydroxystearate2 Aloe Vera Extract-1-30 4.00% Enterococcus lactic acid bacterium heat-treated dead cells 0.01-1% (appropriate amount) (B phase) 56.45% water Glycerin 5.00% Na chloride 1.00% (Phase C) Spice 0.25% Phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben, isobutylparaben 0.30%
  • Phase II Shaving cream (phase II) 100% water Glycerin 3.00% Ethylenediamine disuccinate 3Na 0.30%
  • Phase II Olive oil fatty acid cetearyl, olive oil fatty acid sorbitan mix 3.00% Cetyl palmitate, sorbitan palmitate, sorbitan olive oil fatty acid mix 1.50% Olive oil fatty acid lauryl 4.00% Garcinia indica seed fat 4.00% Stearic acid 0.50% BHT 0.10% Enterococcus lactococci 0.01-1% (appropriate amount)
  • Phase III Polyacrylate-13, polyisobutene, polysorbate 20 0.33%
  • Phase IV Preservatives qs perfume qs
  • phase II (Manufacturing method) Prepare phase I and phase II and heat to 75-80 ° C respectively. Phase II is added to Phase I while homogenizing at 70-75 ° C. with a high-speed stirrer. Cool to 40 ° C. in a water bath with stirring. Add phase III and homogenize with a high speed stirrer. Add phase IV. The viscosity was measured using a B-type viscometer. TC, 10 rpm, room temperature after 24 hours, 6,000 to 18,000 mPa ⁇ s.
  • Body shampoo (I phase) Olive oil PEG-7 Na carboxylate 15.00% Decyl glucoside 10.00% Lauramide propyl betaine 10.00% PEG-120 methyl glucose dioleate 1.50% (Phase II) Olive oil PEG-7 2.00% Olive oil fatty acid ethylhexyl 0.50% Tocopherol 0.25% Appropriate amount of fragrance (phase III) 100% water Betaine 1.00% Panthenol 0.20% Glycerin 3.00% Ethylenediamine disuccinate 3Na 0.30% Hydroxymethylglycine Na 0.50% (Phase IV) Sodium chloride 1.00% (V phase) Lactic acid (80%) 0.25% Enterococcus lactic acid bacterium heat-treated dead cells 0.01-1% (appropriate amount)
  • Lactococci belonging to the genus Enterococcus used as an active ingredient in the present invention changes the ratio of bacterial species in the normal flora of skin. That is, bacteria that produce odorants that are an unpleasant body odor source, such as Staphylococcus, Corynebacterium, and Micrococcus, are specifically reduced, or those bacteria are reduced. Inhibits proliferation. Actually, the effect of suppressing the generation of amine odor, thiol alcohol odor, and 2-nonenal odor in the human body is also recognized, and the production of odorous substances that become unpleasant body odor sources such as armpits, feet, scalp, and genital area is suppressed.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

L'invention concerne un moyen et un médicament destinés chacun à réduire une odeur corporelle déplaisante en réduisant spécifiquement la teneur en une bactérie nocive qui est normalement présente sur la peau. Un agent empêchant la production d'odeur corporelle contient, en tant que principe actif, des cellules de souche Enterococcus faecalis EC-12 (Numéro d'accession: FERM BP-10284); et une préparation externe pour la peau, une composition de blanchisserie et un matériau de feuille hygiénique, chacun utilisant l'agent empêchant la production d'odeur corporelle.
PCT/JP2019/025696 2018-06-28 2019-06-27 Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique WO2020004580A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020527655A JPWO2020004580A1 (ja) 2018-06-28 2019-06-27 乳酸菌を含有する体臭発生抑制剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018122881 2018-06-28
JP2018-122881 2018-06-28

Publications (1)

Publication Number Publication Date
WO2020004580A1 true WO2020004580A1 (fr) 2020-01-02

Family

ID=68984941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/025696 WO2020004580A1 (fr) 2018-06-28 2019-06-27 Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique

Country Status (3)

Country Link
JP (1) JPWO2020004580A1 (fr)
TW (1) TW202012615A (fr)
WO (1) WO2020004580A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000944A1 (en) * 2018-11-09 2022-01-06 The Ritsumeikan Trust Agent for controlling sebaceous glands

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10313853A (ja) * 1997-03-19 1998-12-02 Yuji Mae 微生物含有半流動性組成物、微生物剤並びに使用方法
JP2001299328A (ja) * 2000-04-27 2001-10-30 Sanyo Chem Ind Ltd 粉末状微生物含有組成物
US20130129653A1 (en) * 2010-04-23 2013-05-23 L'oreal Cosmetic use of a lysate of bifidobacterium species for treating body odor
CN104307012A (zh) * 2014-11-05 2015-01-28 双胞胎（集团）股份有限公司 一种畜禽养殖场专用除臭剂及其应用
JP6185041B2 (ja) * 2015-12-04 2017-08-23 一丸ファルコス株式会社 表皮ブドウ球菌由来のグリセロール産生促進剤、皮膚表皮角化細胞由来の抗菌ペプチド産生促進剤、およびそれらの皮膚保護用外用剤への利用
WO2018155660A1 (fr) * 2017-02-24 2018-08-30 Ｒａｐａｓ株式会社 Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10313853A (ja) * 1997-03-19 1998-12-02 Yuji Mae 微生物含有半流動性組成物、微生物剤並びに使用方法
JP2001299328A (ja) * 2000-04-27 2001-10-30 Sanyo Chem Ind Ltd 粉末状微生物含有組成物
US20130129653A1 (en) * 2010-04-23 2013-05-23 L'oreal Cosmetic use of a lysate of bifidobacterium species for treating body odor
CN104307012A (zh) * 2014-11-05 2015-01-28 双胞胎（集团）股份有限公司 一种畜禽养殖场专用除臭剂及其应用
JP6185041B2 (ja) * 2015-12-04 2017-08-23 一丸ファルコス株式会社 表皮ブドウ球菌由来のグリセロール産生促進剤、皮膚表皮角化細胞由来の抗菌ペプチド産生促進剤、およびそれらの皮膚保護用外用剤への利用
WO2018155660A1 (fr) * 2017-02-24 2018-08-30 Ｒａｐａｓ株式会社 Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000944A1 (en) * 2018-11-09 2022-01-06 The Ritsumeikan Trust Agent for controlling sebaceous glands

Also Published As

Publication number Publication date
JPWO2020004580A1 (ja) 2021-08-05
TW202012615A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
KR101217382B1 (ko) α,α-트레할로오스의 당질 유도체를 함유하는 것을 특징으로 하는 피부 외용제
WO2020024703A1 (fr) Composition topique de fullerène soluble dans l'eau
JP2007529445A (ja) 脱臭剤に使用されるプレバイオティク作用を有する物質
JP2008069075A (ja) 皮膚外用組成物
JP2019038754A (ja) 皮膚外用剤
JP2006347906A (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP5239002B2 (ja) 藍草から得られた抗菌活性物質及びこれを含有する各種組成物
JP5241054B2 (ja) コラーゲン合成促進用組成物
JP5765744B2 (ja) アトピー性皮膚炎の予防剤または治療剤、および外用剤
JP2005263794A (ja) コラーゲン合成促進用組成物
JP2005047910A (ja) 皮脂分泌抑制用組成物
WO2020004580A1 (fr) Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique
JP5285203B2 (ja) 血流促進剤並びに該血流促進剤を含有する外用剤、化粧料、浴用剤及び洗剤
JP2006342067A (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP5166116B2 (ja) 育毛剤
JP5216414B2 (ja) 育毛剤
JP2003055188A (ja) シワ形成防止用皮膚外用剤、化粧料及び食品
JPWO2018012157A1 (ja) メラニン産生抑制剤、美白剤、線維芽細胞活性化剤、コラーゲン及び／又はエラスチン産生促進剤、及びシワ改善剤
JP2006137702A (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP2007031316A (ja) 抗変異原性を利用した抗紫外線刺激剤
JP2006347905A (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP2014181208A (ja) 皮膚刺激緩和剤
JP2002322044A (ja) 美白剤及び美白用組成物
JP2004010505A (ja) 化粧料
JP2010018585A (ja) ポリ−γ−Ｌ−グルタミン酸を含有する化粧品組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19825409

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020527655

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19825409

Country of ref document: EP

Kind code of ref document: A1